Arvinas, Inc (ARVN)

Price$10.81

Favorite Metrics

Price vs S&P 500 (26W)7.53%

Price vs S&P 500 (4W)-8.94%

Market Capitalization$703.57M

All Metrics

Book Value / Share (Quarterly)$6.83

P/TBV (Annual)2.13x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)25.96%

Cash Flow / Share (Quarterly)$-4.34

Price vs S&P 500 (YTD)-11.39%

Net Profit Margin (TTM)-30.77%

EPS (TTM)$-1.22

10-Day Avg Trading Volume0.76M

EPS Excl Extra (TTM)$-1.22

Revenue Growth (5Y)64.50%

EPS (Annual)$-1.14

ROI (Annual)-18.60%

Net Profit Margin (5Y Avg)-239.63%

Cash / Share (Quarterly)$10.79

Revenue Growth QoQ (YoY)-83.95%

ROA (Last FY)-11.26%

Revenue Growth TTM (YoY)-0.30%

EBITD / Share (TTM)$-1.63

ROE (5Y Avg)-36.82%

Operating Margin (TTM)-45.13%

Cash Flow / Share (Annual)$-4.34

P/B Ratio1.62x

P/B Ratio (Quarterly)1.76x

Net Income / Employee (Annual)$-0

EV / Revenue (TTM)2.14x

Net Interest Coverage (TTM)-2.48x

ROA (TTM)-9.31%

EPS Incl Extra (Annual)$-1.14

Current Ratio (Annual)4.92x

Quick Ratio (Quarterly)4.85x

3-Month Avg Trading Volume0.86M

52-Week Price Return43.79%

Revenue / Employee (TTM)$1

Tangible BV / Share (Quarterly)$8.31

P/S Ratio (Annual)2.68x

Asset Turnover (Annual)0.37x

52-Week High$14.51

Operating Margin (5Y Avg)-254.02%

EPS Excl Extra (Annual)$-1.14

CapEx CAGR (5Y)-21.56%

Tangible BV CAGR (5Y)370.17%

26-Week Price Return16.28%

Quick Ratio (Annual)4.85x

13-Week Price Return-9.84%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)4.92x

Enterprise Value$561.071

Revenue / Share Growth (5Y)46.34%

Asset Turnover (TTM)0.30x

Book Value / Share Growth (5Y)-12.40%

Revenue / Employee (Annual)$1

Pretax Margin (Annual)-30.65%

Cash / Share (Annual)$10.79

3-Month Return Std Dev56.00%

Net Income / Employee (TTM)$-0

ROE (Last FY)-18.62%

EPS Basic Excl Extra (Annual)$-1.14

P/FCF (TTM)14.13x

Receivables Turnover (TTM)78.39x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-1.22

Receivables Turnover (Annual)78.39x

ROI (TTM)-14.24%

P/S Ratio (TTM)2.68x

Pretax Margin (5Y Avg)-233.90%

Revenue / Share (Annual)$3.70

Tangible BV / Share (Annual)$10.62

Price vs S&P 500 (52W)8.70%

Year-to-Date Return-7.25%

5-Day Price Return3.97%

EPS Normalized (Annual)$-1.14

ROA (5Y Avg)-18.40%

Net Profit Margin (Annual)-30.77%

Month-to-Date Return3.77%

Cash Flow / Share (TTM)$-5.17

EBITD / Share (Annual)$-1.63

Operating Margin (Annual)-45.13%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-36.77%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-1.22

P/TBV (Quarterly)2.63x

P/B Ratio (Annual)1.76x

Pretax Margin (TTM)-30.62%

Book Value / Share (Annual)$6.83

Price vs S&P 500 (13W)-12.70%

Beta1.91x

P/FCF (Annual)1.27x

Revenue / Share (TTM)$4.05

ROE (TTM)-14.25%

52-Week Low$5.90

Analyst Recommendations

Jan 2026

Feb 2026

Mar 2026

Apr 2026

3.73

3.81

Industry Peers — Pharmaceuticals(308)

Symbol	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
ARVNArvinas, Inc	2.68x	-0.30%	—	—	$10.81
LLYEli Lilly & Co.	13.45x	44.70%	83.04%	27.59%	$919.90
JNJJohnson & Johnson	5.82x	7.87%	67.95%	14.90%	$230.69
ABBVABBVIE INC.	5.97x	8.57%	71.62%	-2.88%	$203.71
MRKMerck & Co., Inc.	4.51x	1.31%	78.55%	21.23%	$117.10
AZNAstraZeneca PLC	5.39x	8.63%	81.31%	21.88%	$200.69
NVSNovartis AG	4.87x	8.91%	75.82%	15.26%	$150.99
NVONovo-Nordisk A/S	3.74x	6.43%	80.98%	20.66%	$40.46
ABTAbbott Laboratories	3.71x	6.59%	56.50%	8.20%	$96.00
PFEPfizer Inc.	2.50x	-1.64%	75.81%	-3.51%	$27.52
BMYBristol-Myers Squibb Co.	2.52x	-0.22%	72.63%	—	$59.13

About

Arvinas is a clinical-stage biotechnology company developing targeted protein degradation therapies using its proprietary PROTAC platform, which harnesses the body's natural protein disposal system. The company is advancing a pipeline of clinical-stage candidates in oncology and neurology, including ARV-102, ARV-806, vepdegestrant, and others. The PROTAC approach offers a potentially differentiated mechanism for selectively eliminating disease-causing proteins.